Supernus Up on Report of Progress With ADHD Treatment
Supernus Up on Report of Progress With ADHD Treatment Supernus said that a Phase 3 trial 'met the primary endpoint ... compared to placebo in improving the symptoms of ADHD.' Author: Supernus Pharmaceuticals ( SUPN) - Get Report shares jumped on Wednesday after the drugmaker focused on the central nervous system reported progress in a Phase 3 study of an attention-deficit-hyperactivity-disorder drug. Supernus recently traded at $26.70, up 19%. The stock remains off 2% year to date. “At a daily dose of up to 600mg, the trial met the primary endpoint with robust statistical significance...
Source: thestreet.com